Signals
The AMR Pipeline Is Too Thin for the Threat Ahead
The 2026 AMR Benchmark shows that industry efforts are still being outpaced by drug resistance, with antimicrobial innovation, access, stewardship and manufacturing all under pressure.
TB Diagnosis Moves Closer to the Patient
Hepatitis Elimination Is Still Losing Patients Before Diagnosis
Diabetic Eye Screening Is Becoming Risk-Based
Abu Dhabi Puts Rare Eye Gene Therapy on the Regional Map
AI Eye Screening Has an Image Quality Problem
AI Retinal Screening Moves Into the Diabetes Clinic
India Turns AI Eye Screening Into Public-Health Infrastructure
Africa’s Cardiovascular Decade Is a System-Design Problem
